Neoplasms, Plasma Cell: Clinical Trials

4,369 trials for Neoplasms, Plasma Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2017 completed, 616 recruiting, 578 terminated, 404 unknown. 1905 Phase 2, 1433 Phase 1, 424 Phase 3, 389 Not applicable, 106 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 21905Completed 910, Terminated 294, Recruiting 216, Active not recruiting 173, Unknown 149, Withdrawn 97, Not yet recruiting 55, Suspended 8, Enrolling by invitation 3
Phase 11433Completed 676, Terminated 255, Recruiting 178, Unknown 128, Active not recruiting 93, Withdrawn 53, Not yet recruiting 42, Suspended 7, Enrolling by invitation 1
Phase 3424Completed 214, Recruiting 57, Active not recruiting 54, Unknown 42, Terminated 32, Not yet recruiting 18, Withdrawn 6, Suspended 1
Not applicable389Completed 158, Recruiting 84, Terminated 46, Unknown 44, Not yet recruiting 27, Active not recruiting 14, Withdrawn 12, Suspended 3, Enrolling by invitation 1
Early Phase 1106Recruiting 31, Unknown 24, Completed 16, Not yet recruiting 15, Terminated 7, Withdrawn 6, Active not recruiting 5, Suspended 2
Phase 464Completed 29, Recruiting 11, Unknown 9, Not yet recruiting 6, Active not recruiting 4, Withdrawn 3, Terminated 2

Follow Neoplasms, Plasma Cell: new trials by email Literature Review of Neoplasms, Plasma Cell trials Research Report on Neoplasms, Plasma Cell

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors
Not applicableNot yet recruitingUniversity of Vermont Medical Center332028-02-012026-08-25
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 2Not yet recruitingExcyte Biopharma Ltd642027-12-012026-11-06
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Individual Exercise, Group Exercise - Multiple Myeloma
Not applicableSuspendedMedical University of Vienna452027-09-012026-10-09
Engineered Dendritic Cell Vaccines for Multiple Myeloma
DC vaccines - Multiple Myeloma or Plasmacytoma
Phase 1Not yet recruitingShenzhen Geno-Immune Medical Institute102027-06-302026-11-02
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma
Phase 1WithdrawnFred Hutchinson Cancer Center2027-06-012026-09-11
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 2RecruitingNational Cancer Institute (NCI)802027-05-222026-11-20
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)742027-04-202026-11-18
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1622027-04-122026-10-16
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Phase 2Not yet recruitingZealand University Hospital1502027-03-012026-09-25
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM)
Phase 2Not yet recruitingUniversity of Arkansas502027-03-012026-09-02
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma
Phase 4Not yet recruitingAnne Louise Tølbøll Sørensen4002027-03-012026-03-16
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma
Phase 1Not yet recruitingUniversity of Chicago322027-02-232026-10-22
Teclistamab In Waldenstrom's Macroglobulinemia
Teclistamab - Waldenstrom's Macroglobulinemia
Phase 2Not yet recruitingMassachusetts General Hospital242027-02-192026-09-01
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma
Phase 3Not yet recruitingKite, A Gilead Company7502027-02-012026-11-16
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University702027-01-012026-09-30
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
Isatuximab, VRD - Multiple Myeloma
Phase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University152027-01-012026-10-02
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma
Phase 3Not yet recruitingKite, A Gilead Company6002027-01-012026-10-21
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
CAR-T cells - Multiple Myeloma, Plasmacytoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202026-12-312026-11-02
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
CAR T cells - Multiple Myeloma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202026-12-312026-10-30
A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.3002026-12-302026-11-12

Showing 20 of 4369. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3676)  ·  Lymphoma (653)  ·  Lymphoma, Non-Hodgkin (625)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (609)  ·  Waldenstrom Macroglobulinemia (521)  ·  Lymphoma, Follicular (489)  ·  Lymphoma, B-Cell, Marginal Zone (472)  ·  Hodgkin Disease (468)  ·  Lymphoma, Mantle-Cell (468)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (468)  ·  Recurrence (439)  ·  Lymphoma, Large B-Cell, Diffuse (428)  ·  Leukemia (415)  ·  Leukemia, Myeloid, Acute (381)

Broader conditions

Neoplasms by Histologic Type (4355)  ·  Immune System Diseases (4280)  ·  Immunoproliferative Disorders (4275)  ·  Lymphoproliferative Disorders (4222)  ·  Hemic and Lymphatic Diseases (4166)  ·  Neoplasms (4136)  ·  Paraproteinemias (4134)  ·  Hematologic Diseases (4082)  ·  Cardiovascular Diseases (4037)  ·  Blood Protein Disorders (4035)  ·  Vascular Diseases (4029)  ·  Hemorrhagic Disorders (4028)  ·  Hemostatic Disorders (4022)  ·  Lymphatic Diseases (1345)

Interventions

Dexamethasone (916)  ·  Bortezomib (519)  ·  Lenalidomide (488)  ·  Cyclophosphamide (405)  ·  Melphalan (285)  ·  Calcium Dobesilate (272)  ·  daratumumab (258)  ·  pomalidomide (228)  ·  carfilzomib (192)  ·  fludarabine phosphate (158)  ·  fludarabine (142)  ·  Peripheral Blood Stem Cell Transplantation (137)  ·  Thalidomide (132)  ·  Filgrastim (128)  ·  Rituximab (127)

Sponsors

National Cancer Institute (NCI) (186)  ·  Mayo Clinic (101)  ·  Celgene (93)  ·  Memorial Sloan Kettering Cancer Center (90)  ·  M.D. Anderson Cancer Center (86)  ·  Fred Hutchinson Cancer Center (85)  ·  Janssen Research & Development, LLC (67)  ·  University of Arkansas (59)  ·  Dana-Farber Cancer Institute (55)  ·  Institute of Hematology & Blood Diseases Hospital, China (54)  ·  GlaxoSmithKline (47)  ·  Amgen (43)  ·  Washington University School of Medicine (41)  ·  City of Hope Medical Center (39)  ·  Masonic Cancer Center, University of Minnesota (37)

Countries

United States (2579)  ·  China (498)  ·  France (437)  ·  Spain (339)  ·  Germany (327)  ·  Italy (325)  ·  Canada (282)  ·  United Kingdom (271)  ·  Australia (233)  ·  Greece (184)  ·  South Korea (172)  ·  Japan (168)  ·  Belgium (156)  ·  Israel (145)  ·  Netherlands (142)

Top investigators

Brenda Sandmaier (12)  ·  Robert Knight, MD (11)

Results publications

PMID 32499241, PMID 33357481, PMID 31221778, PMID 37022569, PMID 22689675, PMID 23065508, PMID 23524640, PMID 33218965, PMID 34398557, PMID 35285981, PMID 37192741, PMID 40501401, PMID 28803351, PMID 29567784, PMID 34289038, PMID 35549810, PMID 35985959, PMID 36100310, PMID 38023148, PMID 40000533, PMID 40226119, PMID 40826257, PMID 42287565, PMID 20661232, PMID 22674807, PMID 23897961, PMID 25261096, PMID 25628469, PMID 34182226, PMID 34515338, PMID 35876974, PMID 36762851, PMID 37272512, PMID 37934000, PMID 38402374, PMID 39229471, PMID 40156952, PMID 40396505, PMID 40471585, PMID 40674744, PMID 41313549, PMID 41627370, PMID 18032762, PMID 18032763, PMID 18799726, PMID 19179301, PMID 19238148, PMID 19901114, PMID 20067838, PMID 21160068

NIH funding

2023 (68), P30CA015083 (50), U10CA180820 (43), P30CA015704 (33), 2019 (26), 2017 (25), 2018 (23), P30CA033572 (22), 2014 (21), U10CA032102 (21), U24CA196172 (21), 2025 (20), P30CA006973 (20), P30CA022453 (19), P30CA043703 (19)